Axitinib as a third or further line of treatment in renal cancer: a single institution experience

G. P. Tsironis; Michalis Liontos; Anastasios Kyriazoglou; Konstantinos Koutsoukos; Anna Tsiara; Maria Kaparelou; Roubini Zakopoulou; Aaron B. Cohen; Efi Skafida; Sofia Fontara; Flora Zagouri; Aristotelis Bamias; Meletios A Dimopoulos

doi:10.1186/s12894-020-00618-1

Preprint2020

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Giorgos Tsironis, Michalis Liontos, Anastasios Kyriazoglou, Konstantinos Koutsoukos, Anna Tsiara, Maria Kaparelou, Roubini Zakopoulou, Abis Cohen, Efi Skafida, Sofia Fontara, Flora Zagouri, Aristotelis Bamias, Meletios A Dimopoulos

Preprint2020

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Giorgos Tsironis, Michalis Liontos, Anastasios Kyriazoglou, Konstantinos Koutsoukos, Anna Tsiara, Maria Kaparelou, Roubini Zakopoulou, Abis Cohen, Efi Skafida, Sofia Fontara, Flora Zagouri, Aristotelis Bamias, Meletios A Dimopoulos

Article2022

Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm

Aristotelis Bamias, Roubini Zakopoulou, Kimon Tzannis, Minas Sakellakis, Konstantinos Koutsoukos, Anastasios Kyriazoglou, Aikaterini Panagiotou, Stylianos Armylagos, Konstantinos Rokas, Dimitrios Gotzias, Anna Boulouta, Vassiliki Bozionelou, Konstantinos Stravodimos, Ioannis Varkarakis, Dimitriοs Mavroudis, Meletios A Dimopoulos

Article2005

Carboplatin Hypersensitivity Reactions: A Single Institution Experience

Markella-P. Zorzou, Eleni Efstathiou, Eleni Galani, George Bozas, Efstathios Kastritis, Christos Papadimitriou, Meletios A Dimopoulos, Aristotle Bamias

Article2025

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study

Pasquale Lombardi, Jung Sun Kim, Giulia Francesca Manfredi, Ciro Celsa, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Nidhi Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei‐Fan Hsu, Brooke Wietharn, Marianna Silletta, Alessandro Parisi, Chun‐Yen Lin, Andrea Dalbeni, Gianluca Masi, Martin Schönlein, Johann von Felden,

Axitinib as a third or further line of treatment in renal cancer: a single institution experience

Abstract

Discussion(0)

Related publications

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm

Carboplatin Hypersensitivity Reactions: A Single Institution Experience

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study